An interventional study of Upper GIT endoscopy in Chronic Kidney Diseases and Iron-Deficiency Anemia, sponsored by Walid Ahmed Ragab Abdelhamid. Completed at 1 site in Egypt. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Walid Ahmed Ragab Abdelhamid · Not applicable, Interventional, and Diagnostic
Iron deficiency anemia is very common in CKD patients. Data about gastrointestinal lesions in Arab patients are insufficient.
Iron deficiency anemia without gastrointestinal symptoms needs to be assessed in patients with chronic kidney disease.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 81 is above the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →This is the only study on the registry with Walid Ahmed Ragab Abdelhamid as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Chronic kidney diseases patients with iron deficiency anemia and eGFR ≥ 60 ml/min/1.73 m2
Procedure: Upper GIT endoscopy
Chronic kidney diseases patients with iron deficiency anemia and eGFR \< 60 ml/min/1.73 m2.
Procedure: Upper GIT endoscopy
Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
Rate of upper gastrointestinal endoscopic findings In chronic kidney disease patients with iron deficiency anemia
Detect rate of upper GIT lesions in asymptomatic CKD patients with iron deficiency anemia using endoscopy followed by biopsy and histopathological examination
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.